BETA
Your AI-Trained Oncology Knowledge Connection!
Stay up to date on recent advances in the multidisciplinary approach to cancer.
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC
According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.
Frontline LDRT Plus Atezolizumab Combo Shows Efficacy in ES-SCLC
The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.
Best Practices for the Medical Oncology Boards
A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.
Immunotherapy, Novel Agents May Reshape the Early Breast Cancer Landscape
Heather McArthur, MD, focused on current and future strategies for treating early-stage breast cancer.
Avutometinib/Defactinib Display Safety, Efficacy in Ovarian Cancer Subtype
Among 115 patients treated with avutometinib and defactinib, only 5 deaths occurred in the study, none of which were related to study treatment.
